Spotlight


In this issue of GOLD, we highlight some of the top news stories from the pharmaceutical industry that have come to light over the past few months. The COVID-19 pandemic is still dominating headlines, as vaccines go to trial and research funds are launched, but amid all of this, other partnerships, acquisitions, and appointments are also emerging.


20 April

Novartis reach an agreement with the FDA to sponsor Phase III hydroxychloroquine clinical trials in COVID-19 patients


27 April

ViiV Healthcare announce a £3 million Global HIV and COVID-19 Emergency Response Fund for research into COVID-19 in people living with HIV


04 May

Italian pharmaceutical company Menarini agrees to buy Stemline Therapeutics in a $677 million acquisition


06 May

Gilead announce collaborations with generics firms to fast-track production of remdesivir amid suggestions that the drug may be approved for COVID-19 patients


08 May

AbbVie’s acquisition of Allergan completes, expanding the company’s portfolio in immunology and haematologic oncology


19 May

Moderna announce plans to raise $1.34 billion to fund Phase III trials of a mRNA-based COVID-19 vaccine


21 May

AstraZeneca receive over $1 billion from BARDA to develop, produce, and deliver Oxford University’s COVID-19 vaccine, promising to supply 400 million doses


22 May

Roche’s Tecentriq® is recommended by NICE for treating patients with triple negative breast cancer that has spread across the body


29 May

Sanofi’s former Executive VP of Vaccines, David Loew, is announced as new Ipsen CEO, effective 1st July, replacing David Meek


01 June

FDA grants approval for AstraZeneca’s Brilinta drug for patients with coronary artery disease who are high risk for a first heart attack or stroke


02 June

CSL Behring announce partnership with Seattle Children’s Research Institute, developing stem cell gene therapies for patients with primary immunodeficiency diseases


03 June

The American Thoracic Society announces AstraZeneca’s donation of $500,000 to the organisation’s Crisis Fund for COVID-19 research


FOLLOW US 

  • White Twitter Icon
  • White YouTube Icon

Copyright © 2018 European Medical Group LTD. All rights reserved. Copyright © 2018 European Medical Group LTD. All rights reserved. Gold & EMG-Health is for informational purposes and should not be considered medical advice, diagnosis or treatment recommendation.

Terms and Conditions